Publications

Résultats 511 à 520 sur 563 Publications
Titre Auteurs
Chercheurs du CCNV* / Stagiaires du CCNV**
Année Revue
Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
Therriault, J.**, Lussier, F. Z., Tissot, C.**, Chamoun, M., Stevenson, J., Rahmouni, N.**, Pallen, V., Bezgin, G., Servaes, S., Kunach, P.**, Wang, Y. T.**, Fernandez-Arias, J.**, Vermeiren, M., Pascoal, T. A., Massarweh, G., Vitali, P., Soucy, J. P., Saha-Chaudhuri, P., Gauthier, S.*, & Rosa-Neto, P.* 2023 Alzheimer's & dementia
Alzheimer’s biomarkers from multiple modalities selectively discriminate clinical status: Relative importance of salivary metabolomics panels, genetic, lifestyle, cognitive, functional health and demographic risk markers Sapkota, S., Huan, T., Tran T., Zheng, J., Camicioli, R., Li, L. & Dixon, R.A. 2018 Frontiers in Aging Neuroscience
Alzheimer’s environmental and genetic risk scores are differentially associated with general cognitive ability and dementia severity. Andrews, S.J., McFall, G.P.**, Dixon, R.A.**, Cherbuin, N., Eramudugolla, R., Anstey, K.J. 2019 Alzheimer Disease & Associated Disorders
Alzheimer’s Disease Neuroimaging Initiative. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease. Pascoal T.A.**, Mathotaarachchi S.**, Shin M.**, Park A.Y., Mohades S., Benedet A.L.**, Kang M.S., Massarweh G., Soucy J.P.**, Gauthier S.**, Rosa-Neto P.** 2018 European Journal of Nuclear Medicine and Molecular Imaging
Alzheimer Disease, biomarkers, and clinical symptoms – Quo Vadis?
Montero-Odasso M*, Ismail Z*, Camicioli R* 2020 JAMA Neurology
Allocating Scarce Resources to Persons with Dementia During a Pandemic
Smith EE, Couillard P, Fisk JD, Ismail Z, Montero-Odasso M, Robillard J, Vedel I, Sivananthan S, Gauthier S. 2020 Canadian Geriatrics Journal
Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation
Ruthirakuhan M, Herrmann N*, Andreazza AC, Verhoeff NPLG, Gallagher D, Black SE*, Kiss A, Lanctôt KL* 2019 Geriatr Psychiatry Neurol
Ageism and COVID-19: What does our society’s response say about us?
Fraser S*, Lagacé M, Bongué B, Ndeye N, Guyot J, Bechard L**, Garcia L, Taler V, CCNA Social Inclusion and Stigma Working Group, Adam S, Beaulieu M, Bergeron CD, Boudjemadi V, Desmette D, Donizzetti AR, Éthier S, Garon S, Gillis M, Levasseur M, Lortie-Lussier M, Marier P, Robitaille A, Sawchuk K, Lafontaine C, Tougas F. 2020 Age and Ageing
Ageism and COVID-19: what does our society’s response say about us?
Fraser, S.*, Lagacé, M*, Bongué, B., Ndeye, N., Guyot, J., Bechard, L.**, Garcia, L., Taler, V., Members of the CCNA Social Inclusion and Stigma Working Group*, Adam, S., Beaulieu, M., Bergeron, C.D., Boudjemadi, V., Desmette, D., Donizzetti, A. R., Éthier, S., Garon, S., Gillis, M., Levasseur, M., Lortie-Lussier, M., Marier, P., Robitaille, A., Sawchuk, K., Lafontaine, C., & Tougas, F. 2020 Age and Ageing
Ageism and COVID-19: what does our society’s response say about us?
Fraser, S.*, Lagacé, M*, Bongué, B., Ndeye, N., Guyot, J., Bechard, L.**, Garcia, L., Taler, V.*, Members of the CCNA Social Inclusion and Stigma Working Group*, Adam, S., Beaulieu, M., Bergeron, C.D., Boudjemadi, V., Desmette, D., Donizzetti, A. R., Éthier, S., Garon, S., Gillis, M., Levasseur, M., Lortie-Lussier, M., Marier, P., Robitaille, A., Sawchuk, K., Lafontaine, C., & Tougas, F. 2020 Age and Ageing
Résultats 511 à 520 sur 563 Publications
Go back to top